Introduction
Peripheral exudative haemorrhagic retinopathy (PEHR) is a rare degenerative disease of the peripheral retina characterised by sub-retinal and sub-pigment epithelial haemorrhage and exudation out-width the macula. Clinically, their appearance commonly mimics choroidal and uveal melanoma and are a can common differential for a pseudo-melanomatous mass. Although differentiated from wet age-related macular degeneration (AMD) due to its central localisation, little established evidence exists for the treatment of PEHR.
This unique case demonstrates the novel use of Aflibercept in the treatment and maintenance of PEHR and its prognosis over a 27-month period.
Case Description
A 79-year-old female patient was diagnosed with both eye (BE) PEHR in May 2015. At the time, visual acuity was 48 ETDRS letters in the right eye (RE) and 31 ETDRS letters in the left (LE) due to co-existing centre-involving geographic atrophy. ceptors 1 and 2 whilst Ranibizumab (C 2158 H 3282 N 562 O 681 S 12 ) utilises a mouse-derived monoclonal VEGF antibody [7] . It remains unclear if these differences would contribute to our experiences or those reported elsewhere [6].
To our knowledge this is the first case that describes the use of Aflibercept in the treatment of peripheral exudative haemorrhagic retinopathy after starting Ranibizumab.
Conclusion
Our report provides novel insight into the use Aflibercept using a treat-and-extend management regimen in the management of PEHR, similar to that used in wet AMD. This may allow for both better PEHR disease control and preserved vision where other case reports have found this elusive and contributes further literature to an understudied disease.
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KB provided case identification and access to data, ZA collected the data and wrote the manuscript. All authors reviewed the final manuscript. ic therapy (PDT) and the patient was commenced on a Ranibizumab 0.5 mg in 0.05 ml intravitreal injection (Lucentis®, Gen tech Inc., South San Francisco, CA, USA and Novartis AG, Basel Switzerland). Four weeks on, a review post first dose of Ranibizumab demonstrated no changes in visual acuity, or posterior segment findings (Figure 3) . At this point, the anti-VEGF was altered to Aflibercept 2 mg in 0.05 ml intravitreal injection (Eylea®, Regeneron, Tarrytown, New York, USA and Bayer HealthCare, Berlin, Germany) every four weeks for 8 months. After the first Aflibercept injection, disease resolution was observed; with improvements in visual acuity 52 ETDRS letters (RE), 38 ETDRS letters (LE) and anatomical macular findings such as resolution of intra-retinal fluid and macular haemorrhages observed (Figure 4) . In addition, improvements in patient subjective vision were recorded such as resolving 'dark patches'. After the fourth Aflibercept injection, BE macular haemorrhage and peripheral serous detachments were not present. Peripheral exudation also progressively improved. Eight months on, the overall mode of management was changed from monthly to treat-and-extend, with extensions occurring by one week per visit, to 12 week lies as per August 2017. This has been guided by stable optical coherence tomography images, visual acuity and no patient reported symptoms. In total the patient has had 17 Aflibercept injections with the latest visual acuity 50 ETDRS letters (RE), 31 ETDRS letters (LE).
On review of the literature, there is currently no evidence-base standard for the management of PEHR with current therapeutic options including observation, photodynamic therapy, cryotherapy, vitrectomy and photocoagulation [1] . No evidence exists for the use of Aflibercept, however multiple case reports exist for the use of an alternate anti-VEGF, Bevacizumab [2-5]. Although these case reports demonstrate favourable short-term outcomes, their efficacy longterm remains unclear [2] [3] [4] [5] . In a retrospective case series of nine patients, Seibel, et al. [4] reported no statistical differences between the use of Bevacizumab or Ranibizumab (average of 3 consecutive injections; range 1-5) in functional or anatomical outcomes when used pro re nata. Interestingly, they did report retreatment was required for two out of nine patients after median 14-month interval (range 12-16 months) which has similarly been reported elsewhere with the use of Bevacizumab [3].
The pathophysiological mechanism behind our experience of both Aflibercept and Ranibizumab is poorly understood however might be explained by the higher binding affinity and longer acting duration of Aflibercept when compared to Ranibizumab [6] . In addition, pharmacological differences in the chemical derivation of either anti-VEGF's binding sites exist. Whilst both are recombinant fusion proteins that are bound to human immunoglobulin IgG1, Aflibercept (C 4318 H 6788 N 1164 O 1304 S 32 ) utilises human-derived VEGF binding portions from re-
